Equities

Kopran Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
KOPRAN:NSI

Kopran Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)122.82
  • Today's Change-1.38 / -1.11%
  • Shares traded187.51k
  • 1 Year change-27.67%
  • Beta0.8325
Data delayed at least 15 minutes, as of Mar 06 2026 10:28 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kopran Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (API). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include amoxycillin, ampicillin, cloxacillin, amoxy clauv, flucloxacillin, and phenoxy methyl penicillin. Its non-penicillin-based finished oral dosage forms include macrolides, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, gastroenterology, and respiratory. It has a portfolio, producing over 100 dosage forms. These include tablets, capsules, dry powder, suspension and injectables. Its subsidiary, Kopran Research Laboratories Ltd, manufactures a range of APIs, including Atenolol and Sterile Carbapenems.

  • Revenue in INR (TTM)6.20bn
  • Net income in INR165.43m
  • Incorporated1958
  • Employees1.02k
  • Location
    Kopran LtdParijat House1076, Dr. E. Moses Road, Worli9917MUMBAI 400018IndiaIND
  • Phone+91 2 243661111
  • Fax+91 2 224950363
  • Websitehttps://www.kopran.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
KOPRAN:NSI since
announced
Transaction
value
Kopran Laboratories LtdAnnounced20 Mar 202520 Mar 2025Announced-29.73%23.82m
Data delayed at least 15 minutes, as of Mar 06 2026 10:28 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Amanta Healthcare Ltd-100.00bn-100.00bn3.90bn506.00-------------------------------------------------2.01--189.02------
Haleos Labs Ltd3.48bn198.49m3.93bn592.0019.79--10.801.1365.6665.661,150.43--------5,874,455.00--4.26--7.0537.4832.356.024.76--4.44--2.8512.675.74121.1514.58-8.05--
Medicamen Biotech Ltd1.67bn83.18m4.03bn376.0044.04--30.622.426.756.75126.58--------4,434,471.00--4.69--6.6350.0238.014.338.13--1.75--10.57-9.355.31-34.97-11.77-35.6014.87
Shri Ahimsa Naturals Ltd1.16bn266.73m5.41bn--15.773.1918.984.6814.6514.6561.2372.370.79571.804.75--18.3625.5519.4231.5148.6353.5023.0725.1912.68--0.00--22.8634.7517.3178.7053.34--
Kilitch Drugs (India) Ltd2.07bn264.30m5.59bn187.0020.17--20.082.7015.8715.87123.46--------11,074,770.00--5.16--7.3835.2935.3712.188.41--4.54--0.0028.4730.0582.8699.6434.88--
Anlon Healthcare Ltd1.70bn346.64m5.90bn101.0015.06--16.073.477.377.3737.66------------------38.31--20.39----11.05----80.65--112.46------
Kopran Ltd6.20bn165.43m6.00bn1.02k36.38--17.970.96733.413.41128.28--------6,052,426.00--7.85--11.2534.2032.042.678.66--2.39--29.602.4411.86-24.3412.9033.20--
Fabtech Technologies Ltd3.87bn313.94m6.32bn--14.38--17.531.639.889.88115.92------------------44.01--8.11----------44.46--70.67------
Remus Pharmaceuticals Ltd7.48bn325.59m7.25bn68.0019.772.3616.470.969131.1131.11701.20260.511.899.077.21109,981,700.0010.4414.3718.4428.6013.0119.395.518.391.0735.590.04523.59191.93120.4434.98104.5648.07--
Themis Medicare Ltd3.37bn-174.06m7.27bn1.76k------2.15-1.89-1.8936.52--------1,917,083.00--10.17--14.3862.5660.61-5.1613.52---3.71--9.366.2215.00-31.463.7821.5823.36
Sigachi Industries Ltd4.84bn-762.02m7.40bn1.10k------1.53-1.97-1.9714.66--------4,421,398.00--12.29--16.2150.5751.93-15.3414.80--3.73--4.2322.3828.5521.6627.9148.87--
Anuh Pharma Ltd7.68bn418.22m7.75bn295.0018.53--14.641.014.174.1776.65--------26,023,040.00--10.41--17.0022.2523.955.457.35--116.27--26.592.2416.60-21.1627.05-10.7816.89
Data as of Mar 06 2026. Currency figures normalised to Kopran Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

0.28%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 05 Feb 202660.31k0.13%
American Century Investment Management, Inc.as of 05 Feb 202646.65k0.10%
Dimensional Fund Advisors Ltd.as of 30 Nov 202520.99k0.04%
DFA Australia Ltd.as of 31 Jan 20265.74k0.01%
Motilal Oswal Asset Management Co. Ltd.as of 31 Jan 2026848.000.00%
Bandhan AMC Ltd.as of 31 Jan 2026333.000.00%
More ▼
Data from 31 Dec 2025 - 15 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.